| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $20,988 | 1 | 3 |
Sells | $84,340,198 | 33 | 97 |
| McAvoy David R. | EVP, Chief Legal Officer | 1 | $20,988 | 0 | $0 | $20,988 |
| Savage Brian | Interim Chief Legal Officer | 0 | $0 | 3 | $163,759 | $-163,759 |
| Jover Placid | See "Remarks" | 0 | $0 | 2 | $539,856 | $-539,856 |
| Shields Matthew | EVP, Global Operations | 0 | $0 | 2 | $653,333 | $-653,333 |
| Weiss Amir | Chief Accounting Officer | 0 | $0 | 2 | $672,068 | $-672,068 |
| Fox Christine | EVP, Head of U.S. Commercial | 0 | $0 | 4 | $2M | $-2M |
| Hughes Eric A | See "Remarks" | 0 | $0 | 4 | $4.08M | $-4.08M |
| MIGNONE ROBERTO | director | 0 | $0 | 3 | $8.46M | $-8.46M |
| Daniell Richard | Exec. VP, European Commercial | 0 | $0 | 4 | $9.93M | $-9.93M |
| Kalif Eliyahu Sharon | EVP, Chief Financial Officer | 0 | $0 | 2 | $12.59M | $-12.59M |
| Sabag Mark | See "Remarks" | 0 | $0 | 3 | $14.2M | $-14.2M |
| Francis Richard D | President and CEO | 0 | $0 | 4 | $31.05M | $-31.05M |
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Over the last 12 months, insiders at Teva Pharmaceutical Industries Limited have bought $20,988 and sold $84.34M worth of Teva Pharmaceutical Industries Limited stock.
On average, over the past 5 years, insiders at Teva Pharmaceutical Industries Limited have bought $20,988 and sold $27.75M worth of stock each year.
Highest buying activity among insiders over the last 12 months: McAvoy David R. (EVP, Chief Legal Officer) — $20,988.
The last purchase of 1,113 shares for transaction amount of $20,988 was made by McAvoy David R. (EVP, Chief Legal Officer) on 2025‑09‑05.
| 2026-03-17 | Sale | Sabag Mark | See "Remarks" | 62,102 0.0053% | $30.14 | $1.87M | -1.84% | |
| 2026-03-05 | Sale | Francis Richard D | President and CEO | 20,025 0.0017% | $31.67 | $634,160 | -6.47% | |
| 2026-03-05 | Sale | Hughes Eric A | See "Remarks" | 9,533 0.0008% | $31.67 | $301,895 | -6.47% | |
| 2026-03-05 | Sale | Daniell Richard | EVP, Europe Commercial | 17,295 0.0015% | $31.67 | $547,705 | -6.47% | |
| 2026-03-05 | Sale | Fox Christine | EVP, U.S. Commercial | 7,924 0.0007% | $31.67 | $250,940 | -6.47% | |
| 2026-03-05 | Sale | Savage Brian | Interim Chief Legal Officer | 1,127 <0.0001% | $31.67 | $35,690 | -6.47% | |
| 2026-03-05 | Sale | Shields Matthew | EVP, Global Operations | 17,295 0.0015% | $31.67 | $547,705 | -6.47% | |
| 2026-03-05 | Sale | Jover Placid | See "Remarks" | 14,150 0.0012% | $31.67 | $448,108 | -6.47% | |
| 2026-03-04 | Sale | Francis Richard D | President and CEO | 23,393 0.002% | $32.46 | $759,442 | -9.51% | |
| 2026-03-04 | Sale | Hughes Eric A | See "Remarks" | 11,277 0.001% | $32.46 | $366,102 | -9.51% | |
| 2026-03-04 | Sale | Daniell Richard | EVP, Europe Commercial | 57,833 0.005% | $32.78 | $1.9M | -9.51% | |
| 2026-03-04 | Sale | Fox Christine | EVP, U.S. Commercial | 9,098 0.0008% | $32.46 | $295,362 | -9.51% | |
| 2026-03-04 | Sale | Savage Brian | Interim Chief Legal Officer | 2,675 0.0002% | $32.46 | $86,843 | -9.51% | |
| 2026-03-03 | Sale | Francis Richard D | President and CEO | 442,935 0.037% | $32.36 | $14.33M | -7.45% | |
| 2026-03-03 | Sale | Daniell Richard | EVP, Europe Commercial | 128,985 0.0108% | $32.36 | $4.17M | -7.45% | |
| 2026-03-03 | Sale | Hughes Eric A | See "Remarks" | 80,762 0.0067% | $32.36 | $2.61M | -7.45% | |
| 2026-03-03 | Sale | Savage Brian | Interim Chief Legal Officer | 1,274 0.0001% | $32.36 | $41,227 | -7.45% | |
| 2026-02-26 | Sale | Kalif Eliyahu Sharon | EVP, Chief Financial Officer | 345,810 0.03% | $33.64 | $11.63M | -10.90% | |
| 2026-02-15 | Sale | Francis Richard D | President and CEO | 447,778 0.0393% | $34.22 | $15.32M | -0.33% | |
| 2025-12-16 | Sale | MIGNONE ROBERTO | director | 77,400 0.0068% | $30.24 | $2.34M | +5.18% |
| Francis Richard D | President and CEO | 1170639 0.1005% | $37M | 0 | 11 | |
| MIGNONE ROBERTO | director | 367600 0.0316% | $11.62M | 2 | 5 | +9.88% |
| Sabag Mark | See "Remarks" | 224940 0.0193% | $7.11M | 0 | 9 | |
| Hughes Eric A | See "Remarks" | 107711 0.0093% | $3.4M | 0 | 13 | |
| Daniell Richard | EVP, Europe Commercial | 85755 0.0074% | $2.71M | 0 | 39 | |
| Fox Christine | EVP, U.S. Commercial | 84905 0.0073% | $2.68M | 0 | 5 | |
| Kalif Eliyahu Sharon | EVP, Chief Financial Officer | 57478 0.0049% | $1.82M | 0 | 6 | |
| McAvoy David R. | EVP, Chief Legal Officer | 13027 0.0011% | $411,783.47 | 1 | 0 | |
| Shields Matthew | EVP, Global Operations | 9989 0.0009% | $315,752.29 | 0 | 2 | |
| Savage Brian | Interim Chief Legal Officer | 10914 0.0009% | $344,991.54 | 0 | 3 | |
| Jover Placid | See "Remarks" | 6774 0.0006% | $214,126.14 | 0 | 2 | |
| Weiss Amir | Chief Accounting Officer | 5650 0.0005% | $178,596.50 | 0 | 6 | |
| BARER SOL J | director | 220442 0.0189% | $6.97M | 2 | 0 | +0.5% |
| Dethlefs Sven | EVP, North America Commercial | 165381 0.0142% | $5.23M | 1 | 17 | <0.0001% |
| Crane Rosemary A | director | 33509 0.0029% | $1.06M | 0 | 1 | |
| de Notaristefani Carlo | Executive VP Global Operations | 33589 0.0029% | $1.06M | 0 | 4 | |
| McClellan Michael James | EVP, Chief Financial Officer | 15898 0.0014% | $502,544.38 | 0 | 6 | |
| O'Grady Brendan P. | EVP, North America Commercial | 14868 0.0013% | $469,992.84 | 0 | 17 | |
| Drape Eric | Executive VP Global Operations | 9701 0.0008% | $306,648.61 | 0 | 17 | |
| Shani Eli | EVP,Global Marketing&Portfolio | 9091 0.0008% | $287,366.51 | 0 | 1 | |
| Grant Angus | EVP, Business Development | 8848 0.0008% | $279,685.28 | 0 | 1 | |
| Codner Iris Beck | EVP Global Brand&Communication | 8290 0.0007% | $262,048.03 | 0 | 1 | |
| Stark David Matthew | Exec. VP Chief Legal Officer | 2974 0.0003% | $94,020.47 | 0 | 20 | |
| Fridriksdottir Hafrun | Executive VP, Global R&D | 1387 0.0001% | $43,827.71 | 0 | 22 | |
| Griffin Deborah A | Chief Accounting Officer | 0 0% | $0 | 0 | 12 | |
| Nazzi Gianfranco | EVP, International Markets | 0 0% | $0 | 0 | 14 | |
| Conway Vikki L | See "Remarks" | 0 0% | $0 | 0 | 4 |
$910,099,463 | 123 | 11.52% | $2.13B | |
$25,613,591 | 65 | -3.30% | $11.55B | |
$14,599,168 | 59 | 12.79% | $1.71B | |
$102,709,455 | 46 | 30.55% | $1.01B | |
$11,542,910 | 40 | 56.19% | $1.44B | |
$21,020,549 | 38 | -2.84% | $13.19B | |
$73,312,053 | 38 | -4.38% | $1.57B | |
$12,998,723 | 30 | 3.46% | $4.11B | |
$6,506,230 | 27 | -16.20% | $1.05B | |
$25,034,841 | 20 | 9.38% | $712.56M | |
$78,335,024 | 20 | 4.76% | $50.98B | |
$83,406,412 | 19 | 21.96% | $2.88B | |
$2,233,486 | 16 | -3.31% | $15.96B | |
$1,843,996 | 10 | 22.92% | $996.24M | |
$26,633,903 | 9 | 42.23% | $1.11B | |
$1,718,514 | 9 | 38.13% | $810.01M | |
$141,200 | 8 | 41.74% | $5.46B | |
$725,133 | 7 | 30.62% | $2.23B | |
Teva Pharmaceutical Industries Limited (TEVA) | $32,954,224 | 5 | -0.22% | $36.81B |
| Increased Positions | 340 | +57.82% | 127M | +18.37% |
| Decreased Positions | 242 | -41.16% | 126M | -18.23% |
| New Positions | 130 | New | 24M | New |
| Sold Out Positions | 50 | Sold Out | 26M | Sold Out |
| Total Postitions | 686 | +16.67% | 693M | +0.14% |
| Blackrock, Inc. | $1.79M | 5.04% | 57.8M | +3M | +6.41% | 2025-09-30 |
| Phoenix Financial Ltd. | $1.28M | 3.6% | 41.3M | +4M | +9.36% | 2025-09-30 |
| Menora Mivtachim Holdings Ltd. | $1.2M | 3.39% | 38.92M | +427,000 | +1.11% | 2025-09-30 |
| Harel Insurance Investments & Financial Services Ltd. | $1.17M | 3.29% | 37.7M | +4M | +12.9% | 2025-09-30 |
| Migdal Insurance & Financial Holdings Ltd. | $1.01M | 2.84% | 32.58M | +4M | +13.59% | 2025-09-30 |
| Clal Insurance Enterprises Holdings Ltd | $974,513.00 | 2.75% | 31.49M | -876,000 | -2.71% | 2025-09-30 |
| Lingotto Investment Management Llp | $884,823.00 | 2.49% | 28.59M | +431,872 | +1.53% | 2025-09-30 |
| Rubric Capital Management Lp | $762,918.00 | 2.15% | 24.65M | -1M | -5.19% | 2025-09-30 |
| Fmr Llc | $762,650.00 | 2.15% | 24.64M | -33M | -57.61% | 2025-09-30 |
| Pointstate Capital Lp | $641,049.00 | 1.81% | 20.71M | 0 | 0% | 2025-09-30 |